Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
Burzynski Research Institute Inc. Stock Analysis BZYR
United States Health Care Nano Cap Burzynski Research Institute, Inc. engages in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the trade name Antineoplastons. The company is headquartered in Houston, Texas and currently employs 0 full-time employees. The company went IPO on 2001-10-15. Antineoplastons are useful in the treatment of human cancer. The firm is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The firm conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Clinical trials conducted by the Company primarily use intravenous formulations of Antineoplastons, though few trials also use oral formulations. The firm's clinical trials are conducted at the Burzynski Clinic.
Read More Burzynski Research Institute Inc (BZYR) Chart
Key Statistics of Burzynski Research Institute Inc (BZYR)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.01Volume
3300.00P/E Ratio (TTM)
-52 Week Range
Market Cap
1.42MAvg. Volume
37.57KDividend Yield
-Financial Metrics & Statements of Burzynski Research Institute Inc (BZYR)
FAQ's for Burzynski Research Institute Inc (BZYR)
- According to Musaffa’s Shariah screening methodology, Burzynski Research Institute Inc (BZYR) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Burzynski Research Institute Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Burzynski Research Institute Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Burzynski Research Institute Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Burzynski Research Institute Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Burzynski Research Institute Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.